Second cancer risk in adults receiving autologous haematopoietic SCT for cancer: a population-based cohort study.
IA Bilmon, LJ Ashton, RE Le Marsney, AJ Dodds, TA O'Brien, L Wilcox, I Nivison-Smith, B Daniels, CM Vajdic, undefined CAST study group
Bone Marrow Transplantation | Published : 2014
Population-based evidence on second cancer risk following autologous haematopoietic SCT (HCT) is lacking. We quantified second cancer risk for a national, population-based cohort of adult Australians receiving autologous HCT for cancer and notified to the Australasian Bone Marrow Transplant Recipient Registry 1992-2007 (n=7765). Cancer diagnoses and deaths were ascertained by linkage with the Australian Cancer Database and National Death Index. Standardized incidence ratios (SIRs) were calculated and Cox regression models were used to estimate within-cohort risk factors treating death as a competing risk. During a median 2.5 years follow-up, second cancer risk was modestly increased compared..View full abstract